Hsu Jui, Liu Chiareiy, Liu C P, Tsay Wen-Ing, Li Jih-Heng, Lin Dong-Liang, Liu Ray H
National Bureau of Controlled Drugs, Department of Health, Taipei, Taiwan.
J Anal Toxicol. 2003 Oct;27(7):471-8. doi: 10.1093/jat/27.7.471.
Eight commercially available immunoassays for amphetamines (DRI Amphetamines, CEDIA DAU Amphetamines-Semiquantitative, EMIT d.a.u. Monoclonal Amphetamine/Methamphetamine, Synchron CX Systems AMPH, TDx/TDxFLx Amphetamine/Methamphetamine II, CEDIA Amphetamines/Ecstasy, COBAS INTEGRA Amphetamines, and Abuscreen((R)) OnLine HS Amphetamine/MDMA) are evaluated for their effectiveness in serving as the preliminary test methodology for the analysis of 3,4-methylenedioxymethamphetamine/3,4-methylenedioxyamphetamine (MDMA/MDA) and methamphetamine/amphetamine (MA/AM). Standard solutions (in urine matrix) of MDMA, MDA, MA, and AM are used to determine these immunoassays' reactivities (or cross-reactivities) toward these compounds of interest. Case specimens containing MDMA/MDA and MA/AM are also used to study the correlations of the apparent immunoassay MDMA (or MA) concentrations and the gas chromatographic-mass spectrometric concentrations of these compounds. Data resulting from this study suggest that CEDIA Amphetamines/Ecstasy can best predict the concentrations of MDMA and MA in case specimens and can also detect the presence of MDMA at low levels, whereas Abuscreen OnLine HS Amphetamine/MDMA can detect both MDMA and MA at low concentrations.
对八种市售的苯丙胺免疫分析法（DRI苯丙胺、CEDIA DAU苯丙胺 - 半定量、EMIT d.a.u.单克隆苯丙胺/甲基苯丙胺、Synchron CX Systems AMPH、TDx/TDxFLx苯丙胺/甲基苯丙胺II、CEDIA苯丙胺/摇头丸、COBAS INTEGRA苯丙胺和Abuscreen((R)) OnLine HS苯丙胺/摇头丸）进行评估，以确定它们作为分析3,4 - 亚甲基二氧基甲基苯丙胺/3,4 - 亚甲基二氧基苯丙胺（MDMA/MDA）和甲基苯丙胺/苯丙胺（MA/AM）的初步检测方法的有效性。使用MDMA、MDA、MA和AM的标准溶液（尿液基质中）来确定这些免疫分析法对这些目标化合物的反应性（或交叉反应性）。还使用含有MDMA/MDA和MA/AM的病例标本，研究免疫分析法测得的MDMA（或MA）表观浓度与这些化合物的气相色谱 - 质谱浓度之间的相关性。本研究所得数据表明，CEDIA苯丙胺/摇头丸最能预测病例标本中MDMA和MA的浓度，并且还能检测低水平的MDMA的存在，而Abuscreen OnLine HS苯丙胺/摇头丸能在低浓度下同时检测MDMA和MA。
